1887
  1. Home
  2. A-Z Publications
  3. Journal of Emergency Medicine, Trauma and Acute Care
  4. Volume 2024, Issue 6
  5. Article
6 - Al-Bayan University Scientific Conference
  • ISSN: 1999-7086
  • EISSN: 1999-7094

Abstract

Aneurysmal subarachnoid hemorrhage (aSAH) can cause cerebral vasospasm, which narrows the arteries in the brain and significantly affects the prognosis of the patient. Its limitations persist despite current treatments, which is why new delivery pathways such as the nose-to-brain pathway are being investigated. This non-invasive approach to access the central nervous system allows the blood–brain barrier (BBB) to be avoided and systemic side effects to be reduced. The difficulty of delivering drugs to the brain is a major factor in the pharmaceutical industry's focus on aSAH treatments. As a natural defense mechanism, the BBB severely restricts the ability of most medications to enter brain tissue. This obstacle makes it challenging to develop and administer efficient treatments for aSAH, encouraging more studies in this field. The use of nanotechnology is one way to deliver medication via the BBB and into the central nervous system. One possible approach to administer medications directly to the central nervous system is nose-to-brain transfer. It uses the olfactory and trigeminal nerve pathways, which are directly connected to the brain, to cross the BBB. Nasal mucosal permeability can be increased, systemic adverse effects can be reduced, and targeted pharmaceutical delivery and retention in the brain can be enhanced through nanotechnology-based nose-to-brain drug delivery devices. This article examines how drugs are carried from the nose to the brain, recent advances in nanotechnology-based treatments, and potential uses of these systems in the management of central nervous system disorders.

© 2024 Alkufi, Kassab, licensee HBKU Press.
Loading

Article metrics loading...

/content/journals/10.5339/jemtac.2024.absc.5
2024-11-07
2024-12-05
Loading full text...

Full text loading...

/deliver/fulltext/jemtac/2024/6/jemtac.2024.absc.5.html?itemId=/content/journals/10.5339/jemtac.2024.absc.5&mimeType=html&fmt=ahah

References

  1. Liu Y-F, Qiu H-C, Su J, Jiang W-J. Drug treatment of cerebral vasospasm after subarachnoid hemorrhage following aneurysms. Chin Neurosurg J 2016 Dec;2(4):1–8. doi: 10.1186/s41016-016-0023-x.
     [Google Scholar]
  2. Allah AKA, Abd-Al Hammi SN. Preparation and evaluation of chloramphenicol as thermosensitive ocular in-situ gel. Iraqi J Pharm Sci. 2012;21(2):98–105. doi: 10.31351/vol21iss2pp98-105.
     [Google Scholar]
  3. Jasim IK, Abd Alhammid SN, Abdulrasool AA. Synthesis and evaluation of B-cyclodextrin based nanosponges of 5-Fluorouracil by using ultrasound assisted method. Iraqi J Pharm Sci 2020 Dec 27;29(2):88–98. doi: 10.31351/vol29iss2pp88-98.
     [Google Scholar]
  4. Hussein LS, Al-Khedairy EBH. Solubility and dissolution enhancement of ebastine by surface solid dispersion technique. Iraqi J Pharm Sci 2021 Jun 15;30(1):122–32. doi: 10.31351/vol30iss1pp122-132.
     [Google Scholar]
  5. Alhagiesa AW, Ghareeb MM. The Formulation and Characterization of nimodipine nanoparticles for the enhancement of solubility and dissolution rate. Iraqi J Pharm Sci 2021 Dec 11;30(2):143–52. doi: 10.31351/vol30iss2pp143-152.
     [Google Scholar]
  6. Alkawak RSY, Rajab NA. Lornoxicam-loaded cubosomes: Preparation and in vitro characterization. Iraqi J Pharm Sci 2022 Jun 17;31(1):144–53. doi: 10.31351/vol31iss1pp144-153.
     [Google Scholar]
  7. Raheema DA, Kassab HJ. Preparation and in-vitro evaluation of secnidazole as periodontal in-situ gel for treatment of periodontal disease. Iraqi J Pharm Sci 2022 Dec 23;31(2):50–61. doi: 10.31351/vol31iss2pp50-61.
     [Google Scholar]
  8. Rani K, Paliwal S. A review on targeted drug delivery: Its entire focus on advanced therapeutics and diagnostics. Sch J App Med Sci 2014 Jan;2(1C):328–1. doi: 10.36347/sjams.2014.v02i01.0069.
     [Google Scholar]
  9. Ogawa K, Kato N, Kawakami S. Recent strategies for targeted brain drug delivery. Chem Pharm Bull (Tokyo) 2020;68(7):567–82. doi: 10.1248/cpb.c20-00041 PMID: 32611994.
     [Google Scholar]
  10. Qiu Z, Yu Z, Xu T, Wang L, Meng N, Jin H, Xu B. Novel Nano-Drug Delivery System for Brain Tumor Treatment. Cells 2022 Nov 24;11(23):3761. doi: 10.3390/cells11233761 PMID: 36497021; PMCID: PMC9737081.
     [Google Scholar]
  11. Bahadur S, Naurange T, Baghel P, Sahu M, Yadu K. Targeting the brain: Various approaches and science involved. ScienceRise Pharm Sci 2020 Oct 31;27(5 (27)):4–16. doi: 10.15587/2519-4852.2020.210824.
     [Google Scholar]
  12. DiMeco F, Li KW, Tyler BM, Wolf AS, Brem H, Olivi A. Local delivery of mitoxantrone for the treatment of malignant brain tumors in rats. J Neurosurg 2002 Nov 1;97(5):1173–8. doi: 10.3171/jns.2002.97.5.1173.
     [Google Scholar]
  13. Greig NH. Optimizing drug delivery to brain tumors. Cancer Treat Rev 1987 Mar 1;14(1):1–28. doi: 10.1016/0305-7372(87)90048-X.
     [Google Scholar]
  14. Lu C-T, Zhao Y-Z, Wong HL, Cai J, Peng L, Tian X-Q. Current approaches to enhance CNS delivery of drugs across the brain barriers. Int J Nanomed 2014 May 10;9:2241–57. doi: 10.2147/IJN.S61288 PMID: 24872687; PMCID: PMC4026551.
     [Google Scholar]
  15. Masserini M. Nanoparticles for brain drug delivery. Int Sch Res Notices First published: 21 May 2013;2013. doi: 10.1155/2013/238428.
     [Google Scholar]
  16. Chaudhary K, Parihar S, Sharma D. A critical review on nanoscience advancement: In treatment of viral infection. J Drug Deliv Therapeutics 2021 Nov 15;11(6):225–37. doi: 10.22270/jddt.v11i6.5030.
     [Google Scholar]
  17. Alkufi HK, Salman AH, Taher SS. Principles and advantages of new drug delivery technologies. J Complement Med Res 2023 Jan;14(3):6 doi: 10.5455/jcmr.2023.14.03.02.
     [Google Scholar]
  18. Karmali PP, Chaudhuri A. Cationic liposomes as non-viral carriers of gene medicines: resolved issues, open questions, and future promises. Med Res Rev 2007 Sep;27(5):696–722. doi: 10.1002/med.20090.
     [Google Scholar]
  19. Joshi S, Singh-Moon RP, Wang M, Chaudhuri DB, Holcomb M, Straubinger NL, et al. Transient cerebral hypoperfusion assisted intraarterial cationic liposome delivery to brain tissue. J Neurooncol 2014 May;118(1):73–82. doi: 10.1007/s11060-014-1421-6.
     [Google Scholar]
  20. Wagner S, Peters O, Fels C, Janssen G, Liebeskind A-K, Sauerbrey A, et al. Pegylated-liposomal doxorubicin and oral topotecan in eight children with relapsed high-grade malignant brain tumors. J Neurooncol 2008 Jan;86:175–81. doi: 10.1007/s11060-007-9444-x.
     [Google Scholar]
  21. Wen C-J, Zhang L-W, Al-Suwayeh SA, Yen T-C, Fang J-Y. Theranostic liposomes loaded with quantum dots and apomorphine for brain targeting and bioimaging. Int J Nanomed 2012 Mar 26;7:1599–611. doi: 10.2147/IJN.S29369.
     [Google Scholar]
  22. Abdal-Hammid SN, Kassab H, Hussein LS, Haiss MA, Alkufi HK. Spanlastics nanovesicles: An emerging and innovative approach for drug delivery. Maaen J Med Sci 2023 Sep;2(2):100–7. doi: 10.55810/2789-9136.1027.
     [Google Scholar]
  23. Alkufi HK, Kassab HJ. Formulation and evaluation of sustained release sumatriptan mucoadhesive intranasal in-situ gel. Iraqi J Pharm Sci 2019;28(2):95–104. doi: 10.31351/vol28iss2pp95-104.
     [Google Scholar]
  24. Hadi AS, Ghareeb MM. Rizatriptan benzoate nanoemulsion for intranasal drug delivery: Preparation and characterization. Int J Drug Delivery Technology 2022;12(2):546–52. doi: 10.25258/ijddt.12.2.14.
     [Google Scholar]
  25. Selvaraj K, Gowthamarajan K, Karri VVSR. Nose to brain transport pathways an overview: Potential of nanostructured lipid carriers in nose to brain targeting. Artif Cells Nanomed Biotechnol 2018 Dec;46(8):2088–95. doi: 10.1080/21691401.2017.1420073 Epub 2017 Dec 28. PMID: 29282995.
     [Google Scholar]
  26. Bourganis V, Kammona O, Alexopoulos A, Kiparissides C. Recent advances in carrier mediated nose-to-brain delivery of pharmaceutics. Eur J Pharm Biopharm 2018 Jul;128:337–62. doi: 10.1016/j.ejpb.2018.05.009 Epub 2018 May 4. PMID: 29733950.
     [Google Scholar]
  27. Pires PC, Santos AO. Nanosystems in nose-to-brain drug delivery: A review of non-clinical brain targeting studies. J Control Release 2018 Jan 28;270:89–100. doi: 10.1016/j.jconrel.2017.11.047 Epub 2017 Dec 2.
     [Google Scholar]
  28. Mohsen K, Azzazy HME, Allam NK, Basalious EB. Intranasal lipid nanocapsules for systemic delivery of nimodipine into the brain: In vitro optimization and in vivo pharmacokinetic study. Mater Sci Eng C Mater Biol Appl 2020 Nov;116:111236. doi: 10.1016/j.msec.2020.111236 Epub 2020 Jun 24. PMID: 32806316.
     [Google Scholar]
  29. Lee D, Minko T. Nanotherapeutics for nose-to-brain drug delivery: An approach to bypass the blood brain barrier. Pharmaceutics 2021 Nov 30;13(12):2049. doi: 10.3390/pharmaceutics13122049 PMID: 34959331; PMCID: PMC8704573.
     [Google Scholar]
  30. Kouzehgarani GN, Feldsien T, Engelhard HH, Mirakhur KK, Phipps C, Nimmrich V, et al. Harnessing cerebrospinal fluid circulation for drug delivery to brain tissues. Adv Drug Deliv Rev 2021 Jun 1;173:20–59. doi: 10.1016/j.addr.2021.03.002.
     [Google Scholar]
  31. Jeong SH, Jang J-H, Lee Y-B. Drug delivery to the brain via the nasal route of administration: Exploration of key targets and major consideration factors. J Pharm Investig 2023 Jan;53(1):119–52. doi: 10.1007/s40005-022-00589-5.
     [Google Scholar]
  32. Mathure D, Madan JR, Gujar KN, Tupsamundre A, Ranpise HA, Dua K. Formulation and evaluation of niosomal in situ nasal gel of a serotonin receptor agonist, buspirone hydrochloride for the brain delivery via intranasal route. Pharm Nanotechnol 2018;6(1):69–78. doi: 10.2174/2211738506666180130105919 PMID: 29380709.
     [Google Scholar]
  33. Yadav S, Pawar G, Kulkarni P, Ferris C, Amiji M. CNS delivery and anti-inflammatory effects of intranasally administered cyclosporine-A in cationic nanoformulations. J Pharmacol Exp Ther 2019 Sep;370(3):843–54. doi: 10.1124/jpet.118.254672 Epub 2018 Dec 27. PMID: 30591529; PMCID: PMC6806630.
     [Google Scholar]
  34. Islam SU, Shehzad A, Ahmed MB, Lee YS. Intranasal delivery of nanoformulations: A potential way of treatment for neurological disorders. Molecules 2020 Apr 21;25(8):1929. doi: 10.3390/molecules25081929 PMID: 32326318; PMCID: PMC7221820.
     [Google Scholar]
  35. Eskandari S, Varshosaz J, Minaiyan M, Tabbakhian M. Brain delivery of valproic acid via intranasal administration of nanostructured lipid carriers: in vivo pharmacodynamic studies using rat electroshock model. Int J Nanomed 2011;6:363–71. doi: 10.2147/IJN.S15881 Epub 2011 Feb 15. PMID: 21499426; PMCID: PMC3075902.
     [Google Scholar]
  36. Raya AK, Diringer MN. Treatment of subarachnoid hemorrhage. Crit Care Clin 2014 Oct;30(4):719–33. doi: 10.1016/j.ccc.2014.06.004 Epub 2014 Jul 29. PMID: 25257737.
     [Google Scholar]
  37. Huang R-Q, Jiang F-G, Feng Z-M, Wang T-Y. Nicardipine in the treatment of aneurysmal subarachnoid haemorrhage: A meta-analysis of published data. Acta Neurol Belg 2013 Mar;113(1):3–6. doi: 10.1007/s13760-012-0142-x Epub 2012 Oct 31. PMID: 23111775.
     [Google Scholar]
  38. Stuart RM, Helbok R, Kurtz P, Schmidt M, Fernandez L, Lee K, et al. High-dose intra-arterial verapamil for the treatment of cerebral vasospasm after subarachnoid hemorrhage: Prolonged effects on hemodynamic parameters and brain metabolism. Neurosurgery 2011 Feb;68(2):337–45; discussion 345. doi: 10.1227/NEU.0b013e318201be47 PMID: 21135735.
     [Google Scholar]
  39. Ortega-Gutierrez S, Mayer SA. Is the magnesium era for aneurysmal subarachnoid hemorrhage over? Curr Neurol Neurosci Rep. 2010 Nov;10(6):420–2. doi: 10.1007/s11910-010-0134-2 PMID: 20821078.
     [Google Scholar]
  40. Yamada M, Huang Z, Dalkara T, Endres M, Laufs U, Waeber C, et al. Endothelial nitric oxide synthase-dependent cerebral blood flow augmentation by L-arginine after chronic statin treatment. J Cereb Blood Flow Metab 2000 Apr;20(4):709–17. doi: 10.1097/00004647-200004000-00008 PMID: 10779015.
     [Google Scholar]
/content/journals/10.5339/jemtac.2024.absc.5
Loading
Delivery of nose to brain in the management of cerebral vasospasm in aneurysmal subarachnoid hemorrhage
Journal of Emergency Medicine, Trauma and Acute Care 2024, 5 (2024); https://doi.org/10.5339/jemtac.2024.absc.5
/content/journals/10.5339/jemtac.2024.absc.5
/content/journals/10.5339/jemtac.2024.absc.5
Loading

Data & Media loading...

Keyword(s): aneurysmal subarachnoid hemorrhage, nanotechnology and nose-to-brain pathway

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error